н
т

2	
3	Article Title: Transcriptomic profile of normal breast tissue post-mifepristone treatment:
4	secondary outcomes of a randomized controlled trial
5	
6	Deborah Utjés <sup>1,4</sup> ¶, Nageswara Rao Boggavarapu <sup>1</sup> ¶, Mohammed Rasul <sup>1,2</sup> , Isabelle Koberg <sup>1</sup> ,
7	Alexander Zulliger <sup>1</sup> , Sakthivignesh Ponandai-Srinivasan <sup>1</sup> , Carolina von Grothusen <sup>1</sup> ,
8	Parameswaran Grace Lalitkumar <sup>1</sup> , Kiriaki Papaikonomou <sup>1,4</sup> , Twana Alkasalias <sup>1, 3*</sup> and Kristina
9	Gemzell-Danielsson <sup>1,4,5*</sup>
10	
11	<sup>1</sup> Department of Women's and Children's Health, Karolinska Institutet, Stockholm, Sweden.
12	<sup>2</sup> Department of Pharmaceutical Basic Science, Faculty of Pharmacy, Tishk International
13	University, Erbil, Kurdistan Region, Iraq
14	<sup>3</sup> General Directorate of Scientific Research Center, Salahaddin University-Erbil, Erbil, Kurdi-
15	stan Region, Iraq.
16	<sup>4</sup> Department of Gynecology and Reproductive Medicine, Karolinska University Hospital,
17	Stockholm, Sweden
18	<sup>5</sup> WHO Collaborating Centre, Division of Gynecology and Reproduction, Karolinska University
19	Hospital, Stockholm, Sweden.
20	<sup>¶</sup> Equally contributed authors.
21	* Equally contributed authors
22	
23	
24	
25	

NOTE: This preprint reports new research that has not been certified by peer review and should not be used to guide clinical practice.

26	Corres	ponding	Author:
----	--------	---------	---------

- 27 Twana Alkasalias
- 28 Assistant professor, Ph.D. in cell and tumor biology, Department of Women's and Children's
- 29 Health, Karolinska Institutet
- 30 Biomedicum 4A, Solnavägen 9, 17165, Solna, Stockholm, Sweden
- 31 Phone: +46 7 39 5581 29
- 32 Email: twana.alkasalias@ki.se
- 33
- 34
- 35

#### 36 Author contributions

37 DU: study design, data collection, interpretation, and manuscript writing. NB: data acquisition, 38 designed experiments and analyzed RNA seq data. MR, IK, AZ, SPS, and CvG: Experimental 39 work, and manuscript reviewing. PGL: study design, material collection, manuscript writing 40 and reviewing KP: material collection, manuscript writing and reviewing. TA: Conception, 41 study design, data collection & visualization, analysis, interpretation, and manuscript writing. 42 KGD: Conception, study design, sample collection, critical comments, manuscript writing and 43 funding. 44 45 46 47 48

- 49
- 50

51	Running Title: Impact of mifepristone on breast tissue
52	
53	Article type: Clinical trial
54	
55	Funding Statement: This study was funded by the Swedish Research Council (2012-01981,
56	2017-00932), the Swedish Cancer foundation (5321-9416) and the joint grant from Stockholm
57	County Council and Karolinska Institutet (ALF).
58	
59	Disclosure Statement: The authors have no potential conflicts of interest.
60	
61	
62	Data Sharing Statement: The raw data and processed data files were submitted to Gene
63	Expression Omnibus database with the GEO accession ID GSE252145 (for reviewer access
64	please go to https://www.ncbi.nlm.nih.gov/geo/query/acc.cgi?acc=GSE252145, Enter token
65	qfqnyscmvzmzjcp into the box).
66	
67	
68	Trial registration:
69	Clinical Trial Registration Number: NCT01931657
70	URL: https://classic.clinicaltrials.gov/ct2/show/NCT01931657
71	Date of registration: 20/07/2009
72	Date of enrollment of the first subject: 24/11/2009
73	
74	
75	

## 76 **Capsule:**

Mifepristone may provoke a protective effect against breast carcinogenesis; an enrichment in
 extracellular matrix signaling pathways and an association with breast cancer, particularly
 progesterone receptor positive cases, were observed.

80

#### 81 Abstract

82 Progesterone receptor antagonism is gaining attention due to progesterone's recognized role as 83 a major mitogen in breast tissue. Limited but promising data suggest the potential efficacy of 84 antiprogestins in breast cancer prevention. The present study presents secondary outcomes from 85 a randomized controlled trial and examine changes in breast mRNA expression following 86 mifepristone treatment in healthy women. We analyzed 32 paired breast biopsies from 16 87 healthy premenopausal women at baseline and after two months of mifepristone treatment. In 88 total, twenty-seven differentially expressed genes were identified, with enriched biological 89 functions related to extracellular matrix remodeling. Notably, the altered gene signature 90 induced by mifepristone in vivo was rather similar to the in vitro signature. Furthermore, this 91 expression gene signature was associated with breast carcinogenesis and significantly 92 correlated with progesterone receptor expression status in breast cancer, as validated in The 93 Cancer Genome Atlas dataset using the R2 platform. The present study is the first to explore 94 the breast transcriptome following mifepristone treatment in healthy breast tissue in vivo, 95 enhancing the understanding of progesterone receptor antagonism and its potential protective 96 effect against breast cancer by investigating its action in healthy breast tissue.

97

98

#### 99 Keywords

100 Mifepristone, progesterone signaling, progesterone receptor antagonist, breast cancer

4

## 101 Introduction

The majority of breast cancers are related to reproductive factors (1), implicating endogenous cyclic hormonal exposure affecting breast tumorigenesis. Progesterone has emerged as a major mitogen since proliferation of breast epithelial cells occur during the progesterone-dominated luteal phase (2-4). Among different epithelial cell subtypes, the luminal progenitors serve as breast cancer precursor cell (5). Progesterone acts primarily via a paracrine mechanism to stimulate proliferation of the dominating progesterone receptor (PR)-negative breast cells (2), largely mediated by the downstream mediators RANK-L and WNT4 (3, 6, 7).

High mammographic density (HMD) is another important risk factor of breast cancer (8, 9).
Therefore, the architecture and the crosstalk between the stroma including the extracellular matrix (ECM) and epithelial cells in the context of progesterone exposure, play a vital role in breast cancer initiation process.

113 The mitogenic action of progesterone can be counteracted by PR modulators. There is 114 promising but limited data suggesting the potential efficacy of antiprogesterone in breast cancer 115 prevention (10, 11). Nevertheless, numerous studies have investigated the use of a low 116 continuous dose of antiprogesterone in benign gynecological conditions and breast cancer 117 treatment (12). We hypothesized that antagonizing progesterone signaling may protect against 118 breast carcinogenesis, warranting further clinical and molecular investigations. As a secondary 119 outcome of our randomized controlled trial (RCT) (13), we studied the effects of the PR-120 antagonist mifepristone on normal breast tissue following two months of treatment in healthy 121 premenopausal women.

- 122
- 123
- 124
- 125

#### 126 Materials and methods

127 This study reports the secondary outcome of a prospective, double blind, placebo-controlled RCT with the main outcome to study the impact of pretreatment with a continuous low dose of 128 129 mifepristone on menstrual bleeding patterns in women opting for a levonorgestrel releasing 130 intrauterine device for contraception where the results are published by our group elsewhere 131 (13). The secondary outcome presented here, was to investigate the effect of mifepristone 132 treatment on breast tissue. The study was conducted at Karolinska University Hospital, 133 Stockholm, Sweden from 2009 until 2015 and was approved by the Swedish Medical Products 134 Agency (EudraCT number 2009-009014-40). The study protocol was designed according to the 135 recommendations in the CONSORT statement and was approved by the ethical committee at 136 Karolinska Institutet (Dnr: 2009/144-31/4) prior to recruitment. The trial was registered at 137 clinicaltrials.gov (NCT01931657).

138

#### 139 Subjects

140 Eligible study subjects were healthy premenopausal women aged 18-43 years with regular 141 menstrual cycles lasting 25-35 days and with no contraindications to any of the study 142 treatments. All exclusion criteria are presented in the original study, including use of any 143 hormonal or intrauterine contraception and pregnancy, or breastfeeding two months prior to the 144 study or a history of breast cancer or other malignancies. The trial chart explains the details of 145 the enrolled subjects in the current cohort (Figure S1) and baseline characteristics of the women 146 contributing to paired breast biopsies analyses are presented in Table S1. 147

148 Treatment

Study subjects were randomized into two treatment groups (13). One group was treated with
50 mg mifepristone (one quarter of 200 mg Mifegyne®, Exelgyn) every other day for two

151 months (56 days) starting on the first day of the menstrual cycle. The comparator group received 152 visually indistinguishable B-vitamin tablets (TrioBe® Recip) which were also divided into four 153 parts. For the purpose of the present study, only paired breast samples from the mifepristone 154 treated group were analyzed.

- 155
- 156 Biopsy collection

157 Core needle breast aspiration biopsies were collected at baseline and at the end of the treatment,

under ultrasound guidance from the upper outer quadrant of one breast using a 14-gauge needle

159 with an outer diameter of 2.2 mm. The collected breast tissue was divided into two parts, snap-

160 frozen and stored at -180°C until further processing.

161 In order to do a functional validation with an *in vitro* experiment, we used breast tissue samples

162 from three additional healthy and premenopausal women undergoing mammoplasty procedure.

163 This collection was performed according to a separate study, approved by the ethical committee

164 at Karolinska Institutet (Dnr: 2021-04144) prior to recruitment.

165

166 RNA extraction

167 RNA extraction was performed from 16 paired samples (i.e. 32 samples) using the Purelink<sup>TM</sup>
168 RNA Micro kit in conjunction with TRIzol reagent (Life Technologies). For in vitro studies,
169 the RNA extraction from primary breast cells was performed using Quick-DNA/RNA<sup>TM</sup>
170 Microprep Plus; Zymoresearch. RNA quantification was done using the Qubit RNA High
171 Sensitivity Assay Kit (Invitrogen/ Thermo Fischer).

172

173 *cDNA library construction and sequencing* 

174 Complementary DNA (cDNA) libraries for NGS were constructed from RNA for the 16 paired

175 samples, before and after mifepristone treatment, using the well-established Smart-seq2

176 protocol (14), and been well optimized in our group (15).

177

178 RNA-sequencing data processing and analysis

Quality check of raw sequencing reads was done with FastQC and MultiQC (16). RNA
sequencing (RNA-seq) data analysis was performed with the Partek Flow Genomic Analysis
Software (Partek Inc., St. Louis, Missouri, USA). The detailed analysis optimized by our group
is mentioned in von Grothusen et al (15)

- 183
- 184 Gene ontology and pathway analysis

GO analyses for the functional annotation of the DEGs and enriched pathway analysis were conducted using the g:Profiler database (version e101\_eg48\_p14\_baf17f0) with Benjamini-Hochberg FDR multiple testing correction method applying significance threshold of 0.05 (18).

188 Reactome pathway analysis (19) and Metascape-designet database (20) were also used.

189

#### 190 RT-PCR analysis

191 The extracted RNA samples were converted to cDNA using SuperScript® VILO<sup>TM</sup> kit 192 (Invitrogen®, Thermo Fisher Scientific, Waltham, USA). We validated technically some 193 significantly altered genes obtained by sequencing using Tagman® gene probes namely CCL18 194 (assay ID: Hs00268113 m1), MMP2 assay ID: Hs01548727 m1), COL1A1 (assay ID: 195 Hs00164004 m1), COL1A2 (assay ID: Hs01028956 m1), COL3A1 (assay ID: 196 Hs00943809 m1), and 18s (4319413E) as housekeeping gene (Thermo Fisher Scientific, 197 Walthem, USA). We designed a customized primer sequence for ADAMTS2-1 (Forward 198 primer sequence 'cctgacaacccctacttttgc'; reverse primer sequence 'tgaggatgtcaggtgtcagc') and 199 performed RT-PCR using Sybr-green PCR assay. 20ng of cDNA from 10 samples was used in 200 triplicates in the RT-PCR and analyzed on a One Step Plus Real-time PCR system (Applied

Biosystems, USA) according to the manufactures protocol. Fold change was calculated using the comparative Ct-method. A paired t-test compared the pre- and post-mifepristone treatment groups. To assess the impact of different doses of mifepristone on breast cells in vitro, a twoway ANOVA test was applied after the square root transformation. Significance was considered at a P-value < 0.05. GraphPad Prism 9.1.2 (GraphPad Software Inc., USA) was utilized for the statistical analyses.

207

208 In vitro validation via primary epithelia cell isolation

After breast tissue collection and examination by pathologist, the sample was transferred for tissue digestion and single cells isolation. In brief, the tissue was diced on ice using BSS and DMEM with HEPES. The small tissue fragments were transferred to a mixture of digestion enzymes (hyaluronidase and collagenase 1) and incubated on a rotator at  $37^{\circ}$ C for 4-18 hours. The digested tissue was then filtered through a 100  $\mu$ M strainer, and the resulting flowthrough was cultured using a cocktail of Epicult and mammary media.

215

#### 216 Immunofluorescence

217 Following cell isolation, a total of 50,000 cells were seeded per well in 8-well NuncLab-Tek 218 Chamber Slides (Sigma) and incubated for 72 hours at 37°C in a 5% CO2 incubator. 219 Subsequently, the cells were fixed with 4% paraformaldehyde for 15 minutes at room 220 temperature and then blocked with 2% BSA and 0.1% Triton-X (Sigma) in PBS for 30 minutes 221 at room temperature. Subsequently, the cells were incubated with primary antibodies (CD49f, 222 Rat, #MA5-16884, ThermoFisher Scientific; EPCAM, Goat, R and D Systems Cat# AF960, 223 RRID:AB 355745; CK8, Mouse, Santacruz, sc-8020; CK14, Rabbit, Invitrogen, # MA5-224 32214) in 2% BSA in PBS for 1 hour at RT. After three washes with PBS, the cells were

incubated with the respective secondary antibodies (Alexa Fluor; Donkey anti-Rat 488, Donkey
anti-Goat 594, Donkey anti-Mouse 488, and Goat anti-Rabbit 594) in 2% BSA in PBS for 30
minutes at RT. Finally, the samples were mounted using ProLong Gold Antifade Mounting
Medium with DAPI.

229

230 In vitro drug treatment assay

Primary isolated breast epithelial cells were cultured at a density of 5 x  $10^4$  cells per well in a 12-well plate. On the following day, these cells were subjected to different concentrations of mifepristone treatment (0, 5, 50, and 100  $\mu$ M) for a duration of three days. Subsequently, the cells were collected, and their lysates were prepared at three distinct time points: the baseline before the initiation of treatment, after one-day of treatment, and upon the completion of the three-day treatment period. To ensure robustness and reliability, we employed cells from three different donors for this study. For each experiment, we conducted three independent replicates.

238

## 239 In silico data analysis

240 We employed the R2 Genomics Analysis and Visualization Platform (21) for conducting 241 comparative transcriptomic analysis. This online resource facilitated the examination and 242 assessment of the enrichment gene signature within the breast cancer cohort obtained from 243 TCGA. The user-friendly interface and comprehensive tools provided by R2 allowed for 244 efficiently exploring and statistically validating each gene within the enriched gene cohort. Our 245 approach involved evaluating the differences between normal breast tissue and breast cancer, 246 along with an exploration of their correlation with PR expression and signaling. To ensure 247 statistical robustness, we applied a T-test with false discovery rate correction as a multiple 248 testing approach, employing a P-value cutoff of 0.05.

#### 249 Results

# 250 Modulation of gene expression by mifepristone enriches ECM signaling pathways in normal 251 breast tissue

252 We compared the gene expression profile in normal breast tissue before and after mifepristone treatment. A false discovery rate (FDR) of  $\leq 0.05$  and fold change (FC) of  $\geq 2$  or  $\leq -2$  was 253 254 considered statistically significant and identified 27 differentially expressed genes (DEGs) of 255 which 19 genes were upregulated and 8 genes were downregulated (Table S2). We grouped the 256 27 DEGs and named them Gene signature Enriched to Mifepristone's action on normal Breast 257 (GEM-B). GEM-B represents a set of genes responsive to mifepristone in normal breast tissue. 258 A volcano plot displaying GEM-B among overall gene expression is presented in Figure S2A. To technically validate RNA-seq data at the individual gene level, we employed real-time (RT)-259 260 PCR on the same RNA extracted samples for several genes from the GEM-B (Figure S2B). In 261 line with the transcriptome analysis, the mifepristone treated samples exhibited a significant 262 upregulation of the six validated genes by RT-PCR.

263 To explore the biological context of the DEGs, gene functional enrichment analysis were 264 performed using the g:Profiler database. The results of the top five terms in each of the three 265 Gene Ontology (GO) categories (BP: biological process; CC: cellular component, MF: 266 molecular function) annotated in the database are presented in Table 1. The Reactome pathway 267 analysis demonstrated the upregulated DEGs significantly enriched in 54 biological processes. The top ten of those, were mainly associated with ECM organization (Table S3). The same 268 269 analyses with the downregulated DEGs revealed one significantly enriched term in the GO 270 functional annotation (ontology: MF), namely 'active borate transmembrane transporter 271 activity' with the involvement of solely gene SLC4A1. In the Reactome pathway analysis, there 272 were two genes involved separately in six pathways; gene IL1B (involved in 273 'CLEC7A/inflammasome pathway', 'Interleukin-1 processing', 'cell recruitment' and

274 'purinergic signaling in leishmaniasis infection' and gene LAMA1 (involved in 'laminin
275 interactions' and 'MET activates PTK2 signaling'.

The analysis was validated via a third database, Metascape-designet database. The data set enrichment from designet pathway indicated similarly the enrichment of ECM-related pathways (Figure S3).

279

#### 280 The in vivo effect of mifepristone is comparable to its in vitro effect on normal breast tissue

To further validate the *in vivo* changes in the transcriptomic signature induced by mifepristone treatment, we isolated primary breast epithelial cells and exposed them to varying concentrations of mifepristone (0, 5, 50, and 100  $\mu$ M) during two different treatment periods (one and three days), to study the dose response effect as well as the influence of duration of treatment.

286 First, we characterized the primary isolated cells and assessed the enrichment of distinct 287 epithelial cell subtypes including luminal progenitor, mature luminal, basal, and other stromal 288 cells. The expression of four protein markers (EPCAM, CD49f, CK8, and CK14) was examined 289 (22). Notably, we identified diverse expression patterns; some cells exhibited positivity for 290 CD49f or CK14, indicating a basal phenotype. Mature luminal cells expressed EPCAM or CK8. 291 In contrast, other cells were positive for both CD49f and EPCAM, suggesting a luminal 292 progenitor phenotype (Figure 1A). These findings underscore the significance of the 293 heterogeneity within the isolated cells, emphasizing the need to capture the holistic impact of 294 the drug during in vitro treatment.

Based on our analysis of RNA-seq data from the *in vivo* clinical trial, six candidate genes were
selected among the top upregulated and downregulated ones (CCL18, CTSG, ABI3BP,
LAMA1, IL1b and WNT2) (Figure 1B and Figure S4). Consistent with our findings from the
RNA-seq data, the expression levels of CCL18 and CTSG were upregulated in the *in vitro*

12

299 experiment after longer treatment with higher concentrations, and the same was observed 300 following shorter treatment; except for one patient where CTSG expression showed a non-301 significantly upregulated trend and remained unaffected, respectively. WNT2 demonstrated 302 upregulation in all patients when treated with low doses over a three-day period. Conversely, it 303 exhibited downregulation at higher concentrations during both treatment periods. Notably, 304 ABI3BP demonstrated considerable inter-patient variability; it was both up- and downregulated 305 following different concentrations seen in both treatment periods. LAMA1 was not aligned with 306 its downregulated pattern seen in the RCT cohort; it was mainly upregulated following 307 treatment in vitro. However, the secondly most downregulated DEG, IL1B, was significantly 308 reduced with higher concentrations of mifepristone following longer treatment and the same 309 was seen for two patients following shorter treatment. Interestingly, IL1B showed a significant 310 upregulation with low doses of mifepristone as compared to the untreated cells.

311

#### 312 GEM-B is associated with breast carcinogenesis

Given the recognized protooncogenic effect of progesterone in breast carcinogenesis, we aimed to explore the enrichment of the GEM-B signature within breast cancer samples. To achieve this objective, we systematically examined the expression patterns of our GEM-B signature in the breast cancer dataset from The Cancer Genome Atlas (TCGA) using the R2 platform.

The signature was examined comparing the RNA-seq data of primary breast cancer tissue (n=1101) to normal breast tissue (n=113). The results revealed a notable enrichment of GEM-B in the TCGA data cohort when comparing cancerous to normal tissue. Specifically, 21 out of the 27 signature genes exhibited significant and differential expression when comparing breast cancer to normal breast tissue.

However, this enrichment displayed a dichotomy between cancerous and normal tissue. Out of the 21 significantly correlated genes, 11 were enriched in normal breast tissue compared to

tumor (ABI3BP, CTSG, DPP4, CCL18, OSR2, GRIA3, MMP2, LAMA1, ASPRV1, IL1B,

325 PRR4), while the remaining 10 genes were significantly enriched in tumor tissue compared to

326 normal (COL1A1, COL5A1, COL1A2, COL3A1, WNT2, C1QTNF3, ADAMTS2, GXYLT2,

327 CCDC157, RP1), shown in Figure 2. Our findings underscore a substantial correlation between

328 GEM-B, comprising approximately 77.7% of the signature (21 out of 27 genes), and breast 329 carcinogenesis.

330

## 331 GEM-B is significantly correlated to PR expression status in breast cancer

Having investigated the impact of mifepristone on healthy women, we aimed to explore the potential relevance of the transcriptomic changes resulting from mifepristone treatment in our cohort on PR status of the breast cancer cohort. The TCGA breast cancer dataset facilitated the stratification of the PR status across the entire cohort, with 777 patients classified as PR-positive and 337 patients as PR-negative. We conducted an in-depth analysis of the GEM-B gene list, with a focus on delineating the PR status distinctions within the breast cancer datasets.

with a focus on defineating the PK status distinctions within the breast cancel datasets.

338 Out of the 27 genes within the GEM-B signature, 20 exhibited significant enrichment when

339 comparing the PR status categories. Notably, the majority of the enriched genes demonstrated

a robust correlation with PR expression. Specifically, 17 out of the 20 enriched genes (TPSAB1,

341 TPSB2, C1QTNF3, PIEZO2, CTSG, COL1A2, COL1A1, COL3A1, OSR2, ZNF620, ABI3BP,

342 MMP2, GXYLT2, COL5A1, CCDC157, RP1, ADAMTS2) exhibited higher expression levels

in PR-positive cancer tissue compared to PR-negative counterparts, while only 3 genes (CCL18,

344 SLC4A11, LAMA1) displayed heightened enrichment in PR-negative tissue (Figure 3).

345

## 346 Discussion

347 In the present study, transcriptomic profiling and subsequent bioinformatics analyses were 348 performed to explore gene expression response associated with antagonizing progesterone in

349 breast tissue of healthy premenopausal women. The study focuses on role of endogenous 350 progesterone, enlightening the impact of mifepristone in driving the gene expression patterns 351 and ECM signaling pathways. The findings indicate a correlation with breast carcinogenesis 352 and PR expression status in breast cancer.

353

The cycle driven intermittent progesterone exposure followed by mammary gland regression have been emphasized as important causes of tumorigenesis, as opposed to gradual and continuous elevations during pregnancy or anovulation including lactational amenorrhea (1, 2). RNA-seq from normal breast tissue in the Komen bank allies with progesterone's mitogenic role. About 87% of the upregulated genes in the luteal phase, emphasize paracrine action of RANKL, WNT4, and epiregulin as well as enriched functions of DNA replication, mitosis, and DNA repair (23).

361

To address rising breast cancer incidence (8), exploring novel preventive agents is crucial. Mifepristone, a widely studied PR modulator in various benign gynecological conditions and breast cancer inhibition (12), may also hold potential in breast cancer prevention. In a rodent model, mifepristone had a reverse effect on murine mammary stem cell expansion and progesterone's paracrine effectors (24), although caution is needed in translating animal-based results to human *in vivo* conditions.

368 Only two placebo-controlled trials have assessed the effect of mifepristone in normal 369 premenopausal human breast tissue *in vivo*. Exposure to mifepristone for two or three months, 370 significantly reduced Ki-67 expression in breast tissue (10), suggesting inhibition of breast 371 epithelial cell proliferation, and decreased mitotic age surrogate marker and luminal progenitor 372 cell fraction in all analyzed healthy controls (11).

373

374 Our findings highlight the enrichment of several pathways that directly regulate and drive 375 extracellular structure organization and function. ECM displays a pivotal role in tissue 376 homeostasis; consequently, dysregulation and destruction of ECM dynamics can lead to 377 tumorigeneses and cancer development (25, 26). During the menstrual cycle, it undergoes 378 hormonal regulation, affecting cell signaling and cancer pathways in the mammary gland and 379 the surrounding microenvironment (2). Clinically, HMD is positively associated with collagen, 380 ECM density, and the epithelial and stromal compartments, but negatively with fat tissue (8, 381 9). One of the main structural ECM proteins are collagen which represent a key factor that 382 provide tensile strength to the ECM (26) and in the present study, different collagens (COL1A1, 383 COL1A2, COL3A1, COL5A1) were significantly enriched upon mifepristone treatment. Moreover, both collagen degradation and formation emerged as enriched pathways in our 384 385 material, reflecting an increased remodeling of the ECM compared to baseline. These findings 386 may reflect an ongoing adaptation to mifepristone and a longer treatment protocol might have 387 revealed the eventual direction in which the equilibrium would shift. Nevertheless, it seems that 388 the regulation of ECM plays a central role in progesterone action and progesterone receptor 389 antagonism in the breast.

390

391 A fundamental approach for assessing progesterone signaling involves assessment of the PR 392 expression and the subsequent downstream actions within the signaling pathway. The notable 393 enrichment of 20 genes within the GEM-B signature in PR-positive breast cancer tissue 394 underscores the substantial involvement of progesterone in the development of breast cancer. 395 Furthermore, our findings suggest that blocking progesterone signaling by mifepristone may 396 play a significant role in preventing the initiation of breast cancer. This prompts further avenues 397 for in-depth mechanistic studies, shedding light on the potential of mifepristone as both a 398 preventive and therapeutic strategy for breast cancer.

399

400 To the best of our knowledge, the present study is the first to explore the changes in the 401 transcriptomic landscape and its biological functions following progesterone antagonism with 402 mifepristone treatment in healthy breast tissue *in vivo*. The sample population originates from 403 a double-blind RCT (13), limiting the bias in the results and individual paired samples were 404 used, thus reducing the inter-individual variability. Next Generation Sequencing (NGS) was 405 used to identify DEGs, and the results were validated with RT-PCR, confirming the expression 406 pattern for all six randomly chosen genes; reinforcing that data derived from RNA-seq 407 technology is of robust nature and could be applied for further analyses. However, long-term 408 effects after treatment discontinuation were not elucidated due to lack of follow-up data. Based 409 on indications of ECM remodeling following mifepristone treatment, measurements of breast 410 stiffness and density through mammographies could provide further insights. Even though 411 breast cancer seems to arise predominantly from epithelial cells (2), the stroma of mammary 412 gland comprised mainly of the ECM emerged in our study to play a key role which is in line 413 with a plethora of investigations on breast cancer, even suggesting ECM remodeling as a 414 potential therapeutic target (26).

415

In conclusion, our investigation into PR modulation in normal breast tissue, following mifepristone treatment, uncovers crucial alterations in gene expression patterns. The observed shifts in gene expression, in pathways related to ECM organization, point to the complicated involvement of ECM dynamics. The significant correlation of our enriched signature with the PR expression in breast cancer emphasizes the downstream impact of progesterone. Undoubtedly, comprehensive studies specifically designed to delve into the detailed molecular landscape alterations induced by mifepristone treatment could shed light into the molecular

423 actions of progesterone. Furthermore, such studies may explore whether antagonizing

424 progesterone could accord protective properties in the breast.

425

## 426 Acknowledgments

- 427 We would like to thank research midwife Eva Broberg for patient recruitment support and Dr
- 428 Birgitte Wilczek for offering her kind help in collecting breast biopsies. Our thanks also go to
- 429 Dr. Angelique Flöter Rådestad and Dr. Inkeri Leonardsson Schultz for their contribution in
- 430 providing breast samples from healthy women who underwent reduction mammoplasty
- 431 surgeries.
- 432

## 433 **References**

434 Coelingh Bennink HJT, Schultz IJ, Schmidt M, Jordan VC, Briggs P, Egberts 1. 435 JFM, et al. Progesterone from ovulatory menstrual cycles is an important cause of breast 436 cancer. Breast cancer research : BCR. 2023;25(1):60. 437 Atashgaran V, Wrin J, Barry SC, Dasari P, Ingman WV. Dissecting the Biology 2. 438 of Menstrual Cycle-Associated Breast Cancer Risk. Frontiers in oncology. 2016;6:267. 439 3. Hilton HN, Clarke CL, Graham JD. Estrogen and progesterone signalling in the 440 normal breast and its implications for cancer development. Molecular and cellular 441 endocrinology. 2018;466:2-14. 442 Pedroza DA, Subramani R, Lakshmanaswamy R. Classical and Non-Classical 4. 443 Progesterone Signaling in Breast Cancers. Cancers. 2020;12(9). 444 Skibinski A, Kuperwasser C. The origin of breast tumor heterogeneity. 5. 445 Oncogene. 2015;34(42):5309-16. 446 Brisken C. Progesterone signalling in breast cancer: a neglected hormone 6. 447 coming into the limelight. Nature reviews Cancer. 2013;13(6):385-96. 448 Trabert B, Sherman ME, Kannan N, Stanczyk FZ. Progesterone and Breast 7. 449 Cancer. Endocrine reviews. 2020;41(2):320-44. 450 Britt KL, Cuzick J, Phillips KA. Key steps for effective breast cancer 8. 451 prevention. Nature reviews Cancer. 2020;20(8):417-36. 452 9. Ironside AJ, Jones JL. Stromal characteristics may hold the key to 453 mammographic density: the evidence to date. Oncotarget. 2016;7(21):31550-62. 454 10. Engman M, Skoog L, Söderqvist G, Gemzell-Danielsson K. The effect of 455 mifepristone on breast cell proliferation in premenopausal women evaluated through fine 456 needle aspiration cytology. Human reproduction (Oxford, England). 2008;23(9):2072-9. 457 Bartlett TE, Evans I, Jones A, Barrett JE, Haran S, Reisel D, et al. 11. 458 Antiprogestins reduce epigenetic field cancerization in breast tissue of young healthy women. 459 Genome medicine. 2022;14(1):64.

460 Islam MS, Afrin S, Jones SI, Segars J. Selective Progesterone Receptor 12. 461 Modulators-Mechanisms and Therapeutic Utility. Endocrine reviews. 2020;41(5). 462 13. Papaikonomou K, Kopp Kallner H, Söderdahl F, Gemzell-Danielsson K. 463 Mifepristone treatment prior to insertion of a levonorgestrel releasing intrauterine system for 464 improved bleeding control - a randomized controlled trial. Human reproduction (Oxford, 465 England). 2018;33(11):2002-9. 466 Picelli S, Faridani OR, Bjorklund AK, Winberg G, Sagasser S, Sandberg R. 14. 467 Full-length RNA-seq from single cells using Smart-seq2. Nat Protoc. 2014;9(1):171-81. 468 von Grothusen C, Frisendahl C, Modhukur V, Lalitkumar PG, Peters M, 15. 469 Faridani OR, et al. Uterine fluid microRNAs are dysregulated in women with recurrent 470 implantation failure. Human reproduction (Oxford, England). 2022;37(4):734-46. 471 Ewels P, Magnusson M, Lundin S, Kaller M. MultiQC: summarize analysis 16. 472 results for multiple tools and samples in a single report. Bioinformatics. 2016;32(19):3047-8. 473 Love MI, Huber W, Anders S. Moderated estimation of fold change and 17. 474 dispersion for RNA-seq data with DESeq2. Genome Biol. 2014;15(12):550. 475 18. Reimand J, Arak T, Adler P, Kolberg L, Reisberg S, Peterson H, et al. 476 g:Profiler-a web server for functional interpretation of gene lists (2016 update). Nucleic acids 477 research. 2016;44(W1):W83-9. 478 19. Matthews L, Gopinath G, Gillespie M, Caudy M, Croft D, de Bono B, et al. 479 Reactome knowledgebase of human biological pathways and processes. Nucleic acids 480 research. 2009;37(Database issue):D619-22. 481 20. Zhou Y, Zhou B, Pache L, Chang M, Khodabakhshi AH, Tanaseichuk O, et al. 482 Metascape provides a biologist-oriented resource for the analysis of systems-level datasets. 483 Nature communications. 2019;10(1):1523. 484 21. R2: Genomics Analysis and Visualization Platform [Available from: 485 http://r2.amc.nl. 486 Rosenbluth JM, Schackmann RCJ, Gray GK, Selfors LM, Li CM, Boedicker M, 22. 487 et al. Organoid cultures from normal and cancer-prone human breast tissues preserve complex 488 epithelial lineages. Nature communications. 2020;11(1):1711. 489 Pardo I, Lillemoe HA, Blosser RJ, Choi M, Sauder CA, Doxey DK, et al. Next-23. 490 generation transcriptome sequencing of the premenopausal breast epithelium using specimens 491 from a normal human breast tissue bank. Breast cancer research : BCR. 2014;16(2):R26. 492 24. Ranjan M, Lee O, Cottone G, Mirzaei Mehrabad E, Spike BT, Zeng Z, et al. 493 Progesterone receptor antagonists reverse stem cell expansion and the paracrine effectors of 494 progesterone action in the mouse mammary gland. Breast cancer research : BCR. 495 2021;23(1):78. 496 Walker C, Mojares E, Del Río Hernández A. Role of Extracellular Matrix in 25. 497 Development and Cancer Progression. International journal of molecular sciences. 498 2018;19(10). 499 Bonnans C, Chou J, Werb Z. Remodelling the extracellular matrix in 26. 500 development and disease. Nature reviews Molecular cell biology. 2014;15(12):786-801. 501 502 503 504 505

506	
507	
508	
509	
510	
511	
512	
513	
514	
515	
516	
517	
518	
519	
520	
521	
522	
523	
524	Figure Captions
525	Figure 1. A) Characterization of normal primary breast cell (Basal, luminal progenitor &
526	Mature cells). The upper panel displays immunofluorescent images depicting breast cells
527	stained with CD49f (green) and EPCAM (red), while the lower panel showcases cells stained
528	with CK14 (red) and CK8 (green). Scale bars indicate 50 $\mu$ m. DAPI was used to detect the
529	nuclei. B) Assessment of relative gene expression in normal primary breast cells. Real time

530 PCR analysis was conducted on selected genes (CCL18, CTSG, ABI3BP, WNT2, IL1b, and

LAMA1) to evaluate their expression levels in normal primary breast cells treated with varying
concentrations of mifepristone (control, 5μM, 50μM, 100μM) for a three-day duration.
Statistical significance is denoted as follows: \*p<0.0001; \*\*p<0.01; \*\*\*p<0.001;</li>
\*\*\*\*p<0.0001.</li>

535

**Figure 2.** GEM-NB signature enrichment in breast cancer. Utilizing the R2 platform and the TCGA breast cancer dataset, the expression patterns of each gene within the GEM-NB signature were examined. Comparative analysis involved RNA-seq data between two the groups of primary breast cancer tissue (n=1101) and normal breast tissue (n=113).

540

**Figure 3.** Mifepristone driven transcriptomic changes in the context of PR status in breast cancer. Employing the R2 platform and the TCGA breast cancer dataset, seventeen genes within the GEM-NB signature show significant enrichment in PR positive cohort, whereas three genes were enriched in PR negative cohort. The results are presented as a heatmap illustrating the mean log2 values for each gene, with P values indicated on a log10 scale. The analysis involved RNA-seq data from 1114 breast cancer tissues, comparing PR-positive cases (n=777) to PRnegative cases (n=337).

548

549 **Supplemental figure 1.** Study flow diagram.

\*Paired biopsies = baseline plus follow-up breast biopsies from the same patient.

551

552 **Supplemental figure 2. A)** Volcano plot showing the distribution of the differentially 553 expressed genes (DEGs) between breast samples from baseline and after mifepristone 554 treatment. X-axis represent log2 fold change and Y-axis represent logFDR (adjusted p-value). 555 Black vertical lines show log fold change of - 2 and 2 while the horizontal black line represents

a p-value of 0.05. The points represent genes; red for the upregulated DEGs, blue for the downregulated DEGs and grey for the non-differentially expressed genes. **B**) Assessment of relative gene expression before and after mifepristone treatment. Utilizing the RNA isolated from the breast tissue obtained from RCT, Real time PCR analysis was conducted on selected genes (ADAMTS2-1, CCL18, MMP2, COL1A1, COL1A2 and COL3A1) show a significant upregulation with mifepristone treatment in breast. This is in line with RNA sequencing data. \*p<0.05; \*\*p<0.01; \*\*\*p<0.001.

563

**Supplemental figure 3.** Network of enriched terms for GEM-NB genes as determined by Metascape-designet analysis; showing the significance enrichment of extracellular matrix remodeling pathways. (A) Nodes colored by cluster ID; nodes that share the same cluster ID are typically close to each other. (B) Nodes colored by p-value, where terms containing more genes tend to exhibit more significant p-values.

569

**Supplemental figure 4.** Assessment of relative gene expression in normal primary breast cells. Real time PCR analysis was conducted on selected genes (CCL18, CTSG, ABI3BP, WNT2, IL1b, and LAMA1) to evaluate their expression levels in normal primary breast cells treated with varying concentrations of mifepristone (control,  $5\mu$ M,  $50\mu$ M,  $100\mu$ M) for one day duration. Statistical significance is denoted as follows: \*p<0.0001; \*\*p<0.01; \*\*\*p<0.001; \*\*\*\*p<0.0001.

576

577 Tables

578 Table 1. Top 15 enriched gene ontology terms of differentially expressed upregulated genes as
579 determined by Gene Ontology (GO) analyses.

Term ID	Description	FDR (padj)
---------	-------------	------------

<b>Biological Process</b>		
GO:0030198	Extracellular matrix organization	2.21E-08
GO:0043062	Extracellular structure organization	2.21E-08
GO:0030199	Collagen fibril organization	6.95E-07
GO:0032963	Collagen metabolic process	1.76541E-05
GO:0071230	Cellular response to amino acid stimulus	0.000123191
Cecllular		
Component		
GO:0062023	Collagen-containing extracellular matrix	4.78E-12
GO:0031012	Extracellular matrix	4.59E-11
GO:0098643	Banded collagen fibril	1.13E-08
GO:0005583	Fibrillar collagen trimer	1.13E-08
GO:0098644	Complex of collagen trimers	1.08E-07
Molecular		
Function		
GO:0048407	Platelet-derived growth factor binding	2.76E-08
	Extracellular matrix structural constituent conferring tensile	
GO:0030020	strength	4.1495E-06
GO:0005201	Extracellular matrix structural constituent	1.75112E-05
GO:0004252	Serine-type endopep.dase activity	1.75112E-05
GO:0017171	Serine hydrolase activity	2.17779E-05

FDR=false discovery rate

580

581

## 582 Supplemental table 1. Baseline characteristics of women contributing to paired breast

583 biopsies, before and after mifepristone treatment, expressed as median (range).

584

585 Supplemental table 2. Differentially expressed genes with mifepristone treatment.

586

## 587 Supplemental table 3. Top 10 enriched pathways of the upregulated differentially expressed

588 genes as determined by Reactome pathway analysis.







